title: Exacerbation of Wegener's Granulomatosis following Single Administration of Monoclonal Antibody 17-1A (Panorex((R))) during Adjuvant Immunotherapy of Colon Cancer.
abstract: BACKGROUND: Immunotherapy with monoclonal antibody 17-1A (mAb 17-1A) has been shown effective as an adjuvant treatment in UICC stage III colon carcinoma. Usually, severe side effects are infrequent with mAb 17-1A treatment. CASE REPORT: A 64-year-old man had a 18-month history of recurring arthralgia, sinusitis, and conjunctivits. After curative resection of UICC stage II colon cancer adjuvant treatment with mAb 17-1A was initiated. After the first administration (500 mg) the patient experienced an aggravation of the above-mentioned symptoms which led to the diagnosis of Wegener's granulomatosis with multiorgan involvement. Under immunosuppressive therapy with cyclophosphamide and prednisone, clinical stabilization could be achieved. CONCLUSION: The exacerbation of Wegener's granulomatosis occurred immediately after the first administration of mAb 17-1A. This suggests that mAb 17-1A should be applied cautiously in autoimmune disease. Copyright 2000 S. Karger GmbH, Freiburg
authors.affiliation: Onkologisches Zentrum, III. Medizinische Klinik, Universitätsklinikum Mannheim.
authors.forename: A.
authors.initials: A
authors.lastname: Franz
authors.forename: H.
authors.initials: H
authors.lastname: Bewersdorf
authors.forename: G.
authors.initials: G
authors.lastname: Hartung
authors.forename: Y.
authors.initials: Y
authors.lastname: Dencausse
authors.forename: W.
authors.initials: W
authors.lastname: Queisser